<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01299961</url>
  </required_header>
  <id_info>
    <org_study_id>UCLA Rheumatology RA 001</org_study_id>
    <secondary_id>IND 111281</secondary_id>
    <nct_id>NCT01299961</nct_id>
  </id_info>
  <brief_title>Ultrasound Scores as Indication of Response to Subcutaneous Abatacept in Subjects With Rheumatoid Arthritis</brief_title>
  <official_title>Musculoskeletal Ultrasound as a Marker of Therapeutic Response to Abatacept in Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rheumatoid arthritis (RA) is a chronic inflammatory disease (a long-lasting disease causing
      pain and swelling) associated with significant health problems. It is a difficult disease to
      manage as the disease is often unpredictable. RA causes inflammation (swelling) of the joints
      that can cause joint damage, deformity, and progressive disability and impairment. It is
      estimated that 1% of the world's population suffers from this disease.

      The purpose of this research study is to determine if a change in inflammation seen on the
      ultrasound is a good indicator of how subjects' rheumatoid arthritis is responding to
      treatment of subcutaneous abatacept at 3 weeks, 3 months, 6 months, and 12 months.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>12 Month Change in 7-Joint Ultrasound (US) Inflammatory Score</measure>
    <time_frame>baseline, 12 months</time_frame>
    <description>The 7-joint US inflammatory score includes the addition of synovial hypertrophy scores and power doppler scores.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>12 Month Change in Power Doppler Ultrasound (PDUS) Scores</measure>
    <time_frame>baseline, 12 months</time_frame>
    <description>There were seven different joints in the hands and wrists evaluated to score the PDUS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12 Month Change in Gray-scale Ultrasound (GSUS)</measure>
    <time_frame>baseline, 12 months</time_frame>
    <description>There were seven different joints in the hands and wrists evaluated to score the GSUS.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Subcutaneous Abatacept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will receive an injection of 125 mg of abatacept once a week up to 12 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>abatacept</intervention_name>
    <description>125 mg once a week up to 12 months.</description>
    <arm_group_label>Subcutaneous Abatacept</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Over 18 years old

          2. Has a diagnosis of rheumatoid arthritis

          3. Stable DMARDs for at least 1 month (methotrexate, leflunomide, hydroxychloroquine, or
             sulfasalazine)

          4. Disease activity score DAS28/ESR &gt; 3.2 or all must be met: TJC (tender joint
             count)&gt;=4, SJC (swollen joint count)&gt;=4

          5. Must be able to understand information in the Informed Consent and comply with study
             requirements

          6. Total ultrasound synovitis (inflammation of joint-lining membrane) power Doppler score
             &gt;=1 for at least 2 joints and total synovitis score &gt;=1 for at least 1 joint

        Exclusion Criteria:

          1. Current or prior use of biologic drugs (TNF inhibitors, IL-6 inhibitors, CD20
             inhibitors, IL-1 inhibitors, etc.)

          2. Pregnancy or breast feeding

          3. Daily prednisone &gt; 10mg (stable dose for at least 1 month)

          4. Intra-articular steroid injection of the wrist or joints within last 2 months

          5. History of a concomitant autoimmune disease such as lupus, psoriatic arthritis

          6. History of cancer

          7. Previous exposure to abatacept
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Veena K Ranganath, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCLA David Geffen School of Medicine, Division of Rheumatology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA David Geffen School of Medicine, Division of Rheumatology</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 18, 2011</study_first_submitted>
  <study_first_submitted_qc>February 18, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2011</study_first_posted>
  <results_first_submitted>January 6, 2015</results_first_submitted>
  <results_first_submitted_qc>January 20, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 30, 2015</results_first_posted>
  <last_update_submitted>May 15, 2015</last_update_submitted>
  <last_update_submitted_qc>May 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Dr. Veena Ranganath</investigator_full_name>
    <investigator_title>M.D., Assistant Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>Subcutaneous Abatacept</keyword>
  <keyword>Ultrasound</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abatacept</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 34 RA patients were recruited from the UCLA rheumatology clinics between September 2011 to February 2013. However, we had a total of 9 screen fails.</recruitment_details>
      <pre_assignment_details>Patients enrolled in the study were required to have RA, on stable RA medications, and naive to abatacept.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Subcutaneous Abatacept</title>
          <description>All subjects will receive an injection of 125 mg of abatacept once a week up to 12 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="19"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Subcutaneous Abatacept</title>
          <description>All subjects will receive an injection of 125 mg of abatacept once a week up to 12 months.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>This is a the average age of the cohort that started the mediation, Abatacept 125mg sq qwk.</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.6" spread="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>12 Month Change in 7-Joint Ultrasound (US) Inflammatory Score</title>
        <description>The 7-joint US inflammatory score includes the addition of synovial hypertrophy scores and power doppler scores.</description>
        <time_frame>baseline, 12 months</time_frame>
        <population>Total of 19 patients completed 12 mos</population>
        <group_list>
          <group group_id="O1">
            <title>Subcutaneous Abatacept</title>
            <description>All subjects will receive an injection of 125 mg of abatacept once a week up to 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>12 Month Change in 7-Joint Ultrasound (US) Inflammatory Score</title>
          <description>The 7-joint US inflammatory score includes the addition of synovial hypertrophy scores and power doppler scores.</description>
          <population>Total of 19 patients completed 12 mos</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.4" spread="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Most involved side: Synovitis (S), tenosynovitis (T), and power Doppler (PD) of wrist (dorsal (D), palmar (P), and ulnar (U)); S and T of MCP 2,3 (P, plus D for T); PD of the MCP joints (P and D); S and PD of PIP 2, 3 (P, plus D for PD); S and PD for MTP 2, 4 (D). S and PD graded from 0 to 3, and max individual scores are 27 and 39, respectively. T graded on 0-1 scale; max T score is 5. High score is worse. The 7-joint US score is sum of T, S, and PD scores. Change calculated baseline- month 12.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>11.4</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>13.1</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>12 Month Change in Power Doppler Ultrasound (PDUS) Scores</title>
        <description>There were seven different joints in the hands and wrists evaluated to score the PDUS.</description>
        <time_frame>baseline, 12 months</time_frame>
        <population>As stated previously</population>
        <group_list>
          <group group_id="O1">
            <title>Subcutaneous Abatacept</title>
            <description>All subjects will receive an injection of 125 mg of abatacept once a week up to 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>12 Month Change in Power Doppler Ultrasound (PDUS) Scores</title>
          <description>There were seven different joints in the hands and wrists evaluated to score the PDUS.</description>
          <population>As stated previously</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>7 joints were scanned by power doppler ultra sound of the most affected side: wrist, MCP 2/3, PIP 2/3, and MTP 2/5. PDUS was scored semi-quantitatively on a scale of 0-3 (higher score is worse). The mean score of the 2-3 views obtained for each joint was added across all 7 joints, and the total PDUS (range 0-21) scores were calculated. The change from baseline to 12 months is calculated as the baseline PDUS minus 12 month PDUS.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>3.0</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>3.7</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>12 Month Change in Gray-scale Ultrasound (GSUS)</title>
        <description>There were seven different joints in the hands and wrists evaluated to score the GSUS.</description>
        <time_frame>baseline, 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Subcutaneous Abatacept</title>
            <description>All subjects will receive an injection of 125 mg of abatacept once a week up to 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>12 Month Change in Gray-scale Ultrasound (GSUS)</title>
          <description>There were seven different joints in the hands and wrists evaluated to score the GSUS.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>7 joints were scanned by grey-scale ultra sound of the most affected side: wrist, MCP 2/3, PIP 2/3, and MTP 2/5. GSUS was scored semi-quantitatively on a scale of 0-3 (higher score is worse). The mean score of the 2-3 views obtained for each joint was added across all 7 joints, and the total GSUS (range 0-21) scores were calculated. The change from baseline to 12 months is calculated as the baseline GSUS minus 12 month GSUS.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.19</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.2</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>3.7</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Subcutaneous Abatacept</title>
          <description>All subjects will receive an injection of 125 mg of abatacept once a week up to 12 months.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This is a very small open-label study of 25 patients on a FDA approved drug, where efficacy (by standard validated measures) and safety were not the primary end points.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Veena K. Ranganath, MD, MS Assistant Clinical Professor</name_or_title>
      <organization>UCLA</organization>
      <phone>310-825-3061</phone>
      <email>vranganath@mednet.ucla.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

